Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibiotic concentration and activity in catheter lock solutions
2010-023814-29Phase 4Completed
- Sponsor
- Cima Universidad de Navarra
- Start
- Dec 2010
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of vancomycin, teicoplanin, linezolid, daptomycin, tigecycline and 1 more in catheter-associated bloodstream infection (CRBSI) (5 arms), sponsored by Cima Universidad de Navarra. Primary endpoints: Antibiotic concentration in lock solution at day 10 and Bactericidal activity of antibiotic lock solutions. Started Dec 2010; status: completed.
02
Drugs
vancomycinteicoplaninlinezoliddaptomycintigecycline
03
Conditions
catheter-associated bloodstream infection (CRBSI)
Beyond the preview
Go deeper on 2010-023814-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023814-29.